Corporate Overview

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Read more about Nektar's technology »

View Nektar's R&D pipeline »

View approved products developed with Nektar technology »
News
Contact
Investor Relations
Email:
To contact investor relations via phone »
Media Relations
Email:
Contact media relations via phone »
Business Development and Partnering
Email:
To see the business development team at Nektar »
Careers
Email:
To view and apply to current job opportunities at Nektar »
Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients

 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide